CDT EQUITY INC. Effective Tax Rate
CDT EQUITY INC. (CDT) reported Effective Tax Rate of 0.00% for the 6-month period ending 2026-06-30, per its S-1 filed 2026-09-08.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateContinuingOperations · last filed 2026-09-08
- CDT EQUITY INC. effective income tax rate reconciliation, percent for the quarter ending 2026-03-31 was 0.00%.
- CDT EQUITY INC. effective income tax rate reconciliation, percent for the quarter ending 2025-03-31 was 0.00%.
- CDT EQUITY INC. effective income tax rate reconciliation, percent for the quarter ending 2024-03-31 was 0.00%.
- CDT EQUITY INC. effective income tax rate reconciliation, percent for fiscal 2022 was 48.46%.
| Period end | Effective Income Tax Rate Reconciliation, Percent 3 month | Effective Income Tax Rate Reconciliation, Percent 6 month | Effective Income Tax Rate Reconciliation, Percent 9 month | Effective Income Tax Rate Reconciliation, Percent 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% S-1 · filed 2026-09-08 | |||
| 2026-03-31 | 0.00% 10-Q · filed 2026-07-15 | |||
| 2025-12-31 | 0.00% S-1 · filed 2026-09-08 | |||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | 0.00% S-1 · filed 2026-09-08 | |||
| 2025-03-31 | 0.00% 10-Q · filed 2026-07-15 | |||
| 2024-12-31 | 0.00% S-1 · filed 2026-09-08 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2025-11-13 | |||
| 2024-03-31 | 0.00% 10-Q/A · filed 2025-08-14 | |||
| 2023-09-30 | 0.00% 10-Q/A · filed 2023-11-21 | |||
| 2022-12-31 | 48.46% 10-K · filed 2023-03-28 | |||
| 2022-09-30 | 0.00% 10-Q/A · filed 2023-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |